Santarus taps Ventiv force for Zegerid

Share this article:
Specialty pharma company Santarus has hired 140 sales reps from contract sales firm inVentiv Commercial Services to bolster efforts behind its heartburn treatment Zegerid.

Santarus expects the new sales reps to be trained and in place by early 2007, both companies said in a joint news release.

At press time, Santarus, along with co-promotion partner Otsuka America Pharmaceutical, deployed a Zegerid sales force of 370 members to promote Zegerid.

“We believe the additional sales representatives will significantly increase our call frequency and share of voice with the 26,000 high prescribing PPI physicians we currently target,” said Santarus CEO Gerald Proehl in a statement.

Zegerid received its fist FDA approval, for a powder for suspension formulation, in 2004. Capsules received approval in February 2006, followed by chewable tablets in March 2006.

Santarus and inVentiv Commercial Services have been working together since the
August 2004 launch of Zegerid.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...